TriSalus Showcases PEDD Platform Data Across Multiple Tumor Applications at SIR 2026
Event summary
- TriSalus will present new clinical and preclinical data on its Pressure Enabled Drug Delivery (PEDD) platform at the SIR 2026 Annual Scientific Meeting (April 11–15, 2026).
- Three key presentations will cover hepatic tumor penetration, neuroendocrine tumor embolization, and uterine artery embolization applications.
- TriSalus highlights the versatility of PEDD across multiple disease states and therapeutic approaches.
- The company is in final stages of data completion for multiple phase 1 clinical trials involving its investigational immunotherapy nelitolimod.
The big picture
TriSalus' presentation at SIR 2026 underscores the growing importance of targeted drug delivery systems in oncology. The company's PEDD platform represents a strategic shift toward precision medicine in interventional radiology, potentially expanding treatment options for patients with solid tumors. The breadth of applications demonstrated—from liver tumors to uterine artery embolization—highlights the platform's versatility and commercial potential. Success in these presentations could position TriSalus as a key player in the evolving landscape of cancer treatment technologies.
What we're watching
- Clinical Validation
- Whether the new data will demonstrate sufficient efficacy to accelerate PEDD adoption in interventional oncology.
- Partnership Potential
- The pace at which TriSalus can secure development partnerships following completion of its phase 1 trials.
- Market Expansion
- How quickly TriSalus can expand PEDD applications beyond liver-directed therapies into other solid tumor indications.
Related topics